1. RR is a 45-year-old woman who has been living with type 2 diabetes, hypertension, and dyslipidemia for the past six years. She also smokes one pack per day. She uses metformin 1000 mg by mouth twice daily and has used subcutaneous exenatide XR 2 mg weekly for the past several years to manage her diabetes. Her A1C has been consistently around 8% for the past year. Four months ago, she was hospitalized for a stroke. In addition to smoking cessation, management of her hypertension, and use of a statin and aspirin, what adjustments can she make to her antihyperglycemic therapy to reduce her risk for a subsequent major adverse cardiovascular event?

2. At what point should the new once-weekly subcutaneously injected GLP-1 be started in HC?

3. Which subcutaneously injected GLP-1 RA is the best option for HC given his desire to lower his risk of nausea and improve his glycemic control?

« Return to Activity